Paul Sorajja, MD
Dr. Paul Sorajja is the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center at the Minneapolis Heart Institute Foundation, and a cardiologist at Minneapolis Heart Institute® where he serves as the Director of the Center for Valve and Structural Heart Disease. He received his medical degree from Mayo Medical School, and completed his Internal Medicine Residency and Cardiology Fellowship at the Mayo Graduate School of Medicine. During 1998-99, he was a clinical research fellow in myopathy at St. George’s Hospital in London, UK. Dr. Sorajja joined the Mayo Clinic staff in 2006, achieving the rank of Professor of Medicine in 2012. In 2013, Dr. Sorajja joined the Minneapolis Heart Institute® at Abbott Northwestern Hospital.
Dr. Sorajja’s expertise is interventional cardiology, with a focus on bringing the latest innovative technologies to patients with valvular and structural heart disease. He was part of the team that performed the first transcatheter mitral valve replacement (TMVR) in the US, and has the largest worldwide experience with the therapy. Dr. Sorajja currently serves as a national investigator for TMVR and also for clinical trials in percutaneous treatment for tricuspid regurgitation. He has served on several national practice committees for valvular heart disease and hypertrophic cardiomyopathy. Dr. Sorajja has published more than 250 manuscripts and several books. He routinely lectures at national and international medical conferences, and has received awards for his expertise in medical education. Dr. Sorajja is also highly active in developing intellectual property in these areas.
- Heart valve disease (e.g., mitral regurgitation, aortic stenosis, tricuspid regurgitation)
- Structural heart disease and interventions
- Hypertrophic cardiomyopathy
- Coronary atherosclerosis
- Percutaneous coronary intervention